https://www.biopharminternational.com/view/title-the-biopharm-brief-rna-editing-cardiac-remodeling-rare-disease-gene-therapy2026-06-03T19:11:08.122Z2026-06-03T19:11:08.122Z https://www.biopharminternational.com/view/design-sweden-atmp-systems2026-06-03T18:08:10.082Z2026-06-03T18:08:10.082Z https://www.biopharminternational.com/view/ehmt1-gene-therapy-for-kleefstra-syndrome-enters-preclinical-collaboration2026-06-03T17:28:29.111Z2026-06-03T17:28:29.111Z https://www.biopharminternational.com/view/lilly-licenses-ascidian-rna-exon-editing-platform-for-inherited-kidney-diseases2026-06-03T17:05:57.236Z2026-06-03T17:05:57.236Z https://www.biopharminternational.com/view/tenaya-reports-interim-tn-201-data-in-mybpc3-associated-hcm2026-06-03T16:46:42.460Z2026-06-03T16:46:42.460Z https://www.biopharminternational.com/view/ensuring-the-highest-purity-in-injectable-formulations-with-maxipure-polysorbate-802026-06-03T12:01:00Z2026-06-03T12:01:00Z https://www.biopharminternational.com/view/the-biopharm-brief-gene-therapy-reform-cancer-trial-endpoints-and-a-1-2b-rare-disease-deal2026-06-02T21:46:17.883Z2026-06-02T21:46:17.883Z https://www.biopharminternational.com/view/eli-lilly-signs-up-to-1-2b-licensing-deal-for-hanmi-glp-2-therapy-in-short-bowel-syndrome2026-06-02T21:33:00Z2026-06-02T21:33:00Z https://www.biopharminternational.com/view/fda-draft-guidance-could-streamline-rare-disease-gene-therapy-development2026-06-02T21:07:14.071Z2026-06-02T21:07:14.071Z https://www.biopharminternational.com/view/basel-innovation-park-main-campus-expands-flexible-infrastructure-biopharma-startups-manufacturing2026-06-02T19:38:00Z2026-06-02T19:38:00Z https://www.biopharminternational.com/view/the-new-biopharma-playbook-seven-technologies-defining-drug-development-in-20262026-06-02T17:36:00Z2026-06-02T17:36:00Z https://www.biopharminternational.com/view/izalontamab-brengitecan-dual-survival-endpoints-phase-3-tnbc-esophageal-cancer-trials2026-06-02T14:23:37.545Z2026-06-02T14:23:37.545Z https://www.biopharminternational.com/view/advancing-viral-safety-with-next-generation-sequencing-regulatory-expectations-validation-and-real-world-applications2026-06-02T13:06:00Z2026-06-02T13:06:00Z https://www.biopharminternational.com/view/the-biopharm-brief-smarter-immunotherapy-stronger-responses-longer-survival2026-06-01T21:13:00Z2026-06-01T21:13:00Z https://www.biopharminternational.com/view/pumitamig-plus-chemotherapy-shows-high-response-rates-across-pd-l1-levels-and-nsclc-subtypes-in-phase-2-rosetta-lung-02-interim-analysis2026-06-01T14:59:00Z2026-06-01T14:59:00Z https://www.biopharminternational.com/view/ima401-shows-early-clinical-activity-in-mage-a4-positive-solid-tumors-supporting-bispecific-tcr-development-strategy2026-06-01T14:48:02.628Z2026-06-01T14:48:02.628Z https://www.biopharminternational.com/view/ivonescimab-improves-overall-survival-in-phase-iii-harmoni-6-trial-for-squamous-nsclc2026-06-01T19:57:24.422Z2026-06-01T13:53:00Z https://www.biopharminternational.com/view/shaping-the-future-of-microbial-development-from-gene-to-gmp2026-06-01T13:06:00Z2026-06-01T13:06:00Z https://www.biopharminternational.com/view/getting-to-the-point-of-care-bringing-manufacturing-to-the-patient2026-05-30T16:29:00Z2026-05-30T16:29:00Z https://www.biopharminternational.com/view/the-biopharm-brief-billion-dollar-bet-smarter-immunotherapy-hepatitis-b-hope2026-05-29T21:13:56.284Z2026-05-29T21:13:56.284Z https://www.biopharminternational.com/view/dr-alexander-shoushtari-discusses-five-year-kimmtrak-data-and-the-future-of-tcr-therapy-in-metastatic-uveal-melanoma2026-05-29T19:55:00Z2026-05-29T19:55:00Z https://www.biopharminternational.com/view/kimmtrak-data-challenge-long-held-assumptions-about-immunotherapy-in-uveal-melanoma2026-05-29T19:26:24.262Z2026-05-29T19:26:24.262Z https://www.biopharminternational.com/view/fxb0871-pd-1-attenuated-il-2-fusion-protein-phase-1-clinical-china2026-05-29T16:01:02.767Z2026-05-29T16:01:02.767Z https://www.biopharminternational.com/view/bepirovirsen-achieves-phase-3-functional-cure-rates-in-chronic-hepatitis-b-supporting-potential-shift-beyond-lifelong-therapy2026-05-29T15:17:00Z2026-05-29T15:17:00Z https://www.biopharminternational.com/view/pfizer-innovent-biologics-forge-10-5-billion-oncology-collaboration-to-advance-next-generation-cancer-therapies2026-05-29T14:26:05.600Z2026-05-29T14:26:05.600Z https://www.biopharminternational.com/view/systemic-immune-activation-linked-to-improved-outcomes-with-eftilagimod-alfa-in-metastatic-breast-cancer-study2026-05-28T19:17:00Z2026-05-28T19:17:00Z https://www.biopharminternational.com/view/filling-gaps-in-sustainable-packaging2026-05-28T19:15:00Z2026-05-28T19:15:00Z https://www.biopharminternational.com/view/study-finds-comparable-car-t-outcomes-across-accredited-and-non-accredited-centers2026-05-28T18:43:00Z2026-05-28T18:43:00Z https://www.biopharminternational.com/view/tailoring-strategies-to-apac-s-diverse-clinical-trial-environment2026-05-28T16:00:00Z2026-05-28T16:00:00Z https://www.biopharminternational.com/view/phase-3-herizon-gea-01-data-published-in-nejm-reinforce-zanidatamab-s-potential-in-her2-positive-gastroesophageal-cancer2026-05-28T15:41:00Z2026-05-28T15:41:00Z https://www.biopharminternational.com/view/is-your-annex-1-strategy-a-static-document-or-a-dynamic-defense-2026-05-28T15:07:00Z2026-05-28T15:07:00Z https://www.biopharminternational.com/view/biohub-open-source-ai-model-targets-protein-design-for-drug-discovery2026-05-28T14:06:33.688Z2026-05-28T14:06:33.688Z https://www.biopharminternational.com/view/small-molecules-to-complex-biologics-mastering-bioanalytical-workflows-using-high-resolution-mass-spectrometry-hrms-2026-05-28T13:06:00Z2026-05-28T13:06:00Z https://www.biopharminternational.com/view/why-lyophilization-projects-fail-and-how-to-get-it-right2026-05-28T12:01:00Z2026-05-28T12:01:00Z https://www.biopharminternational.com/view/the-biopharm-brief-dermatology-data-and-autoimmune-innovation2026-05-27T19:55:22.361Z2026-05-27T19:55:22.361Z https://www.biopharminternational.com/view/basel-expands-life-sciences-ecosystem-biotech-investment2026-05-27T18:00:00Z2026-05-27T18:00:00Z https://www.biopharminternational.com/view/vir-biotechnology-reports-96-week-phase-2-hepatitis-delta-data-for-tobevibart-and-elebsiran-combination2026-05-27T17:04:00Z2026-05-27T17:04:00Z https://www.biopharminternational.com/view/jade-biosciences-initiates-first-in-human-phase-1-trial-of-baff-r-antibody-jade2012026-05-27T15:40:00.156Z2026-05-27T15:40:00.156Z https://www.biopharminternational.com/view/apogee-s-zumilokibart-advances-toward-phase-3-after-positive-phase-2-atopic-dermatitis-results2026-05-27T15:04:19.589Z2026-05-27T15:04:19.589Z https://www.biopharminternational.com/view/olezarsen-cuts-pancreatitis-events-severe-hypertriglyceridemia-analysis2026-05-27T13:51:31.520Z2026-05-27T13:51:31.520Z https://www.biopharminternational.com/view/trends-in-manufacturing-ebook-may-20262026-05-27T12:01:00Z2026-05-27T12:01:00Z https://www.biopharminternational.com/view/the-biopharm-brief-gene-editing-myeloma-neuroregeneration2026-05-26T21:43:29.819Z2026-05-26T21:43:29.819Z https://www.biopharminternational.com/view/supply-chain-execution-in-radiopharma-the-industry-s-next-critical-challenge2026-05-26T20:09:00Z2026-05-26T20:09:00Z https://www.biopharminternational.com/view/subcutaneous-infliximab-shows-promise-for-durable-patient-centered-ibd-care2026-05-26T18:41:57.013Z2026-05-26T18:41:48.506Z https://www.biopharminternational.com/view/ai-automation-early-planning-shape-future-advanced-therapy-manufacturing-dr-alan-smith2026-05-26T18:00:00Z2026-05-26T18:00:00Z https://www.biopharminternational.com/view/eli-lilly-s-verve-102-gene-editing-therapy-shows-durable-ldl-cholesterol-reduction-in-phase-1-study2026-05-26T16:26:00Z2026-05-26T16:26:00Z https://www.biopharminternational.com/view/late-stage-car-t-bispecific-therapies-drive-transformation-in-the-multiple-myeloma-pipeline2026-05-26T15:46:22.356Z2026-05-26T15:46:22.356Z https://www.biopharminternational.com/view/tfg-001-shows-preclinical-reinnervation-signals-in-parkinson-s-disease-models2026-05-26T13:35:17.252Z2026-05-26T13:35:17.252Z https://www.biopharminternational.com/view/the-expanding-role-of-u-hplc-and-lc-ms-in-next-generation-biopharmaceuticals2026-05-26T13:06:00Z2026-05-26T13:06:00Z https://www.biopharminternational.com/view/the-biopharm-brief-oncology-growth-validation2026-05-22T20:22:22.765Z2026-05-22T20:22:22.765Z https://www.biopharminternational.com/view/subcutaneous-infliximab-may-improve-convenience-adherence-and-sustained-remission-in-ibd-care2026-05-22T20:06:32.941Z2026-05-22T20:06:32.941Z https://www.biopharminternational.com/view/paul-lopolito-adc-cleaning-validation-risk-based-approach-highly-potent-drug-manufacturing2026-05-22T17:00:00Z2026-05-22T17:00:00Z https://www.biopharminternational.com/view/kelun-biotech-reports-positive-phase-3-results-for-sac-tmt-in-first-line-triple-negative-breast-cancer2026-05-22T14:43:00Z2026-05-22T14:43:00Z https://www.biopharminternational.com/view/vosoritide-meets-primary-endpoint-in-phase-3-hypochondroplasia-trial-prompting-planned-snda-submission-to-fda2026-05-22T14:34:08.342Z2026-05-22T14:34:08.342Z https://www.biopharminternational.com/view/the-biopharm-brief-weight-loss-oncology-longevity2026-05-22T00:06:30.313Z2026-05-22T00:06:30.313Z https://www.biopharminternational.com/view/circio-ceo-highlights-circular-rna-potential-for-safer-more-efficient-gene-therapy2026-05-21T20:35:00.000Z2026-05-21T20:35:00Z https://www.biopharminternational.com/view/site-centered-startup-predictability-imperfect-system2026-05-21T18:32:25.437Z2026-05-21T18:32:25.437Z https://www.biopharminternational.com/view/merck-advances-phase-3-adc-study-in-metastatic-colorectal-cancer2026-05-21T17:28:00Z2026-05-21T17:28:00Z https://www.biopharminternational.com/view/lilly-reports-up-to-28-3-weight-loss-with-retatrutide-in-phase-3-obesity-trial2026-05-21T15:21:00.000Z2026-05-21T15:30:00Z https://www.biopharminternational.com/view/industrializing-machine-learning-artificial-intelligence-life-sciences2026-05-21T15:10:32.782Z2026-05-21T15:10:32.782Z https://www.biopharminternational.com/view/ava-bio-austrianova-advance-klotho-cell-therapy-manufacturing-step2026-05-21T13:44:30.757Z2026-05-21T13:44:30.757Z https://www.biopharminternational.com/view/why-high-concentration-biologics-demand-a-new-approach-to-formulation-science2026-05-21T12:01:00Z2026-05-21T12:01:00Z https://www.biopharminternational.com/view/the-biopharm-brief-rna-editing-liver-safety-joint-gains2026-05-20T21:00:00Z2026-05-20T21:00:00Z https://www.biopharminternational.com/view/why-manufacturing-scalability-concerns-should-not-limit-cell-therapy-design2026-05-20T20:36:00Z2026-05-20T20:36:00Z https://www.biopharminternational.com/view/novo-nordisk-highlights-semaglutide-liver-safety-and-subgroup-data-in-mash-at-easl-20262026-05-20T16:37:00Z2026-05-20T16:37:00Z https://www.biopharminternational.com/view/wve-006-rna-editing-therapy-achieves-mz-like-phenotype-in-alpha-1-antitrypsin-deficiency-phase-1b-2a-trial2026-05-20T14:25:00Z2026-05-20T14:25:00Z https://www.biopharminternational.com/view/bimzelx-demonstrates-superior-joint-outcomes-over-risankizumab-in-psoriatic-arthritis-be-bold-trial2026-05-20T13:53:00Z2026-05-20T13:53:00Z https://www.biopharminternational.com/view/the-biopharm-brief-smarter-platforms-safer-therapies-ai-acceleration2026-05-19T21:37:28.250Z2026-05-19T21:37:28.250Z https://www.biopharminternational.com/view/circular-rna-may-transform-aav-gene-therapy-says-circio-ceo-erik-wiklund2026-05-19T20:35:00.000Z2026-05-19T20:35:42.037Z https://www.biopharminternational.com/view/predictive-models-and-raw-immunogenicity-data-could-reshape-preclinical-development-says-vibha-jawa2026-05-19T19:00:00Z2026-05-19T19:00:00Z https://www.biopharminternational.com/view/why-the-need-to-expand-industry-focus-beyond-gene-editing-toward-scalable-cell-therapy-manufacturing-2026-05-19T18:15:00Z2026-05-19T18:15:00Z https://www.biopharminternational.com/view/jcr-pharmaceuticals-highlights-preclinical-cns-gene-therapy-data-for-just-aav-platform-at-asgct-20262026-05-19T15:57:36.361Z2026-05-19T15:57:36.361Z https://www.biopharminternational.com/view/hansa-biopharma-signs-115-million-imlifidase-licensing-agreement-with-serb2026-05-19T15:05:00Z2026-05-19T15:05:00Z https://www.biopharminternational.com/view/incyte-partners-with-edison-scientific-to-integrate-ai-across-drug-discovery-and-translational-research2026-05-19T14:13:00Z2026-05-19T14:13:00Z https://www.biopharminternational.com/view/the-biopharm-brief-adc-expansion-early-breast-cancer-biosimilar-momentum2026-05-18T20:14:30.795Z2026-05-18T20:14:30.795Z https://www.biopharminternational.com/view/integra-therapeutics-targets-next-generation-car-t-development-with-ficat-gene-writing-platform2026-05-18T18:38:57.500Z2026-05-18T18:38:57.500Z https://www.biopharminternational.com/view/regeneron-expands-conjugate-platform-strategy-through-parabilis-medicines-collaboration2026-05-18T17:11:48.081Z2026-05-18T17:11:48.081Z https://www.biopharminternational.com/view/fda-expands-enhertu-into-early-her2-positive-breast-cancer-with-dual-new-indications2026-05-18T16:07:00Z2026-05-18T16:07:00Z https://www.biopharminternational.com/view/solving-qc-bottlenecks-and-enabling-scalable-fully-automated-qc2026-05-18T15:50:55.897Z2026-05-18T15:50:55.897Z https://www.biopharminternational.com/view/fda-approves-first-golimumab-biosimilars-from-accord-biopharma2026-05-18T14:51:00Z2026-05-18T14:51:00Z https://www.biopharminternational.com/view/how-advanced-analytics-partnerships-enhance-the-biopharma-value-chain2026-05-18T13:06:00Z2026-05-18T13:06:00Z https://www.biopharminternational.com/view/the-biopharm-brief-oncology-momentum-car-t-advances-strategic-expansion2026-05-15T21:08:27.444Z2026-05-15T21:08:27.444Z https://www.biopharminternational.com/view/imfinzi-plus-bcg-reduces-early-recurrence-risk-in-high-risk-nmibc-exploratory-potomac-analyses-show2026-05-15T19:13:00Z2026-05-15T19:13:00Z https://www.biopharminternational.com/view/imviva-highlights-early-remission-data-for-allogeneic-car-t-therapy-in-lupus-at-asgct-20262026-05-15T18:11:00Z2026-05-15T18:11:00Z https://www.biopharminternational.com/view/biogen-expands-complement-disease-portfolio-through-acquisition-of-apellis-pharmaceuticals2026-05-15T16:52:00Z2026-05-15T16:52:00Z https://www.biopharminternational.com/view/translational-intelligence-cdmo-atmp2026-05-15T15:34:54.820Z2026-05-15T15:34:54.820Z https://www.biopharminternational.com/view/the-biopharm-brief-immunotherapy-wins-next-gen-car-t-and-hope-for-duchenne-patients2026-05-14T20:33:31.752Z2026-05-14T20:33:31.752Z https://www.biopharminternational.com/view/eu-s-midba-framework-could-eliminate-repetitive-pk-bridging-studies-for-auto-injectors2026-05-14T19:00:00Z2026-05-14T19:00:00Z https://www.biopharminternational.com/view/iv-to-subcutaneous-drug-reformulations-gain-momentum-through-streamlined-regulatory-pathways2026-05-14T19:00:00Z2026-05-14T19:00:00Z https://www.biopharminternational.com/view/sequential-pk-study-designs-may-further-accelerate-iv-to-subcutaneous-biologic-development2026-05-14T19:00:00Z2026-05-14T19:00:00Z https://www.biopharminternational.com/view/regenxbio-reports-positive-phase-3-affinity-duchenne-results-for-rgx-202-gene-therapy2026-05-14T18:53:00Z2026-05-14T18:53:00Z https://www.biopharminternational.com/view/create-medicines-secures-122-million-advance-in-vivo-car-t-pipeline2026-05-14T15:00:00Z2026-05-14T15:00:00Z https://www.biopharminternational.com/view/astrazeneca-s-volga-trial-shows-survival-benefit-for-perioperative-imfinzi-regimen-in-muscle-invasive-bladder-cancer2026-05-14T13:52:00Z2026-05-14T13:52:00Z https://www.biopharminternational.com/view/expanding-cdmo-capabilities-drug-manufacturing2026-05-14T13:47:47.512Z2026-05-14T13:47:47.512Z https://www.biopharminternational.com/view/ai-drug-development-tools-value2026-05-14T12:00:00Z2026-05-14T12:00:00Z https://www.biopharminternational.com/view/how-mechanistic-modeling-advances-car-t-cell-therapy-development2026-05-13T19:30:00Z2026-05-13T19:30:00Z https://www.biopharminternational.com/view/benchmarking-quality-systems-in-cell-and-gene-therapy-insights-from-yelena-ionova2026-05-13T19:00:00Z2026-05-13T19:00:00Z https://www.biopharminternational.com/view/fda-and-ema-requirements-converge-for-cell-and-gene-therapy-cmc-but-gmp-gaps-persist2026-05-13T19:00:00Z2026-05-13T19:00:00Z https://www.biopharminternational.com/view/how-biologic-developers-are-using-optimized-platforms-and-operations-to-reach-first-in-human-trials2026-05-13T18:36:47.188Z2026-05-13T18:36:47.188Z https://www.biopharminternational.com/view/novo-nordisk-highlights-weight-loss-and-mobility-benefits-of-oral-wegovy-at-eco20262026-05-13T15:40:00Z2026-05-13T15:40:00Z